TerraPower Isotopes, a TerraPower subsidiary, plans to increase its actinium-225 production 20-fold by opening a new manufacturing facility in Philadelphia, Pa., and by expanding the capacity of its Everett, Wash., facility. On March 17, TerraPower Isotopes said it expects the new facility to begin producing the medical radioisotope for targeted alpha therapy in 2029.

TerraPower Isotopes, a subsidiary of Bellevue, Wash.–based TerraPower, announced it is now producing actinium-225 at commercial scale, making the medical isotope available to the pharmaceutical industry through weekly production runs. As a result, TerraPower Isotopes said its actinium, after further manufacturing, is now used in multiple drug developers’ radiopharmaceuticals in human clinical trials across the globe.

Westinghouse and TerraPower, in conjunction with Belgium’s Pan Tera, have announced plans to produce large quantities of actinium-225, a radioisotope used for targeted alpha radiation therapy for certain types of cancer.